Mesoblast (MEOBF) Amortization of Deferred Charges (2014 - 2023)
Mesoblast's (MEOBF) quarterly Amortization of Deferred Charges came in at $4.5 million in Q2 2023, up 2.3% year-over-year from $4.4 million in Q2 2022, and down 10.69% quarter-over-quarter from $5.0 million in Q1 2023.
Analysis
Mesoblast (MEOBF) Amortization of Deferred Charges (2014 - 2023) Analysis & Trends
Mesoblast has disclosed Amortization of Deferred Charges across 9 years of filings, most recently posting $4.5 million for Q2 2023.
- In Q2 2023, Amortization of Deferred Charges rose 2.3% year-over-year to $4.5 million; the TTM figure through Jun 2023 stood at $20.1 million (up 16.39% YoY), while the FY2026 annual figure was $23.7 million, up 3.53% from the prior year.
- Amortization of Deferred Charges came in at $4.5 million for Q2 2023 at Mesoblast, down from $5.0 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $6.1 million in Q4 2022 to a low of $2.2 million in Q3 2019.
- Average Amortization of Deferred Charges over 5 years is $4.2 million, with a median of $4.4 million recorded in 2022.
- Year-over-year, Amortization of Deferred Charges jumped 63.38% in 2021 and rose 2.3% in 2023.
- Over 5 years, Amortization of Deferred Charges stood at $2.2 million in 2019, then grew by 17.04% to $2.5 million in 2020, then surged by 93.37% to $4.9 million in 2021, then advanced by 25.18% to $6.1 million in 2022, then fell by 27.42% to $4.5 million in 2023.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $4.5 million in Q2 2023, $5.0 million in Q1 2023, and $6.1 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 4.45 Mn |
| Mar 31, 2023 | 4.99 Mn |
| Dec 31, 2022 | 6.13 Mn |
| Sep 30, 2022 | 4.55 Mn |
| Jun 30, 2022 | 4.35 Mn |
| Mar 31, 2022 | 3.90 Mn |
| Dec 31, 2021 | 4.90 Mn |
| Sep 30, 2021 | 4.14 Mn |
| Sep 30, 2020 | 2.53 Mn |
| Sep 30, 2019 | 2.17 Mn |
| Sep 30, 2018 | 1.76 Mn |
| Dec 31, 2016 | 614,000.00 |
| Sep 30, 2016 | 1.04 Mn |
| Jun 30, 2016 | 1.77 Mn |
| Dec 31, 2015 | 2.03 Mn |
| Sep 30, 2015 | 2.42 Mn |
| Jun 30, 2015 | 1.34 Mn |
| Sep 30, 2014 | 1.94 Mn |